February 1, 2013
The Society of Nuclear Medicine and Molecular Imaging (SNMMI), along with the American College of Radiology (ACR), the American College of Cardiology (ACC) and the American Society of Nuclear Cardiology (ASNC), recently submitted a comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding their proposed decision memo for positron emission tomography.
CMS’s proposal would remove the national non-coverage decision for PET for FDA-approved oncologic applications. The letter stated that while we believe this to be a step in the right direction, we do not think it is comprehensive enough. We requested that CMS modify the proposed decision and finalize that local Medicare Administrative Contractors (MACs) may determine coverage within their respective jurisdictions for positron emission tomography (PET) using radiopharmaceuticals for their labeled indications that are approved by the FDA.
You can find the joint society letter below.